SG Blocks, Inc. — Form 10-Q Summary
Filing identity: The request identifies Olenox Industries Inc., but the supplied filing is for SG Blocks, Inc. (Nasdaq: SGBX). This summary covers the filing provided, for the quarter ended September 30, 2022; financial statements are unaudited.
Business context and reporting period
SG Blocks designs and builds modular structures, provides engineering and project-management services, operates medical testing activities, and has real estate development and environmental segments. The filing reports results for the three and nine months ended September 30, 2022, compared with the same periods in 2021.
Key financial metrics
| Metric | Q3 2022 | Q3 2021 | Nine months 2022 | Nine months 2021 |
|---|---|---|---|---|
| Revenue | $4.13 million | $8.85 million | $20.29 million | $29.89 million |
| Gross profit (loss) | ($0.17 million) | ($0.61 million) | $3.09 million | $2.09 million |
| Gross margin | Approximately (4%) | Approximately (7%) | 15.25% | Approximately 7% |
| Operating loss | ($2.50 million) | ($2.73 million) | ($3.41 million) | ($3.81 million) |
| Net loss | ($2.55 million) | ($2.75 million) | ($3.06 million) | ($3.74 million) |
| Net loss attributable to SG Blocks common stockholders | ($2.45 million) | ($3.83 million) | ($4.59 million) | ($7.41 million) |
| Net cash used in operating activities | Not separately presented | Not separately presented | ($5.55 million) | ($1.03 million) |
For the nine-month period, revenue fell 32.1%, primarily because medical revenue declined $12.27 million; construction growth partially offset the decline. Q3 revenue decreased approximately 53%, driven by a $6.73 million reduction in medical revenue. Nine-month gross margin improved, which management attributed mainly to the absence of losses on a legacy SG Echo contract that had been affected by material cost escalation and labor overruns in 2021. Q3 gross margin remained negative.
At September 30, 2022, cash and cash equivalents were $2.12 million, current assets were $11.87 million, current liabilities were $7.75 million, and total stockholders’ equity was $18.26 million. The company reported $2.50 million of short-term notes payable and $0.75 million of long-term notes payable; operating and finance lease liabilities totaled approximately $2.67 million. The $2.50 million short-term note was extended to January 14, 2023. Cash declined from $13.02 million at December 31, 2021.
Nine-month cash used in investing activities was $3.55 million and cash used in financing activities was $1.80 million, resulting in a $10.91 million net decrease in cash. Investing included $2.00 million of property and equipment purchases, $0.50 million invested in non-marketable securities, and $0.15 million advanced to equity affiliates. Financing included $2.25 million of distributions to non-controlling interests, partly offset by $0.50 million of short-term borrowing.
Material changes versus the prior comparable period
- Medical revenue contracted substantially as COVID-related testing volumes declined. Medical revenue represented 57% of nine-month revenue, versus 80% in 2021.
- Construction and engineering revenue rose to $8.65 million from $5.98 million for the first nine months. Construction gross performance improved significantly year over year.
- Operating cash use increased to $5.55 million from $1.03 million, and cash on hand fell by $10.91 million from year-end 2021.
- Payroll and related expenses increased to $3.65 million from $2.67 million, mainly due to higher stock-based compensation; nine-month stock compensation was $1.87 million versus $0.78 million.
- Backlog was $2.59 million at September 30, 2022, down from $3.22 million at December 31, 2021. The filing says the remaining backlog was expected to convert within one year.
Outlook, risks, contingencies, and unusual items
- Liquidity and going concern: Management said cash was expected to fund obligations for at least twelve months from the report date, relying on operating revenue, cost containment, alliances, and potential future financing. The company has no additional funding secured. The filing also says recurring losses and negative operating cash flows raise substantial doubt about continued operations if additional revenue or financing is not obtained.
- Backlog uncertainty: Management expected the $2.59 million backlog to be realized by December 31, 2022, but noted that contracts may be cancelled, deferred, or changed and may not generate profit. Backlog includes a $5.95 million ATCO contract in the rollforward discussion, while reported ending backlog is lower; investors should review the detailed contract schedule.
- Customer concentration: Three customers accounted for approximately 93% of Q3 revenue; two customers accounted for approximately 88% of nine-month revenue. Two customers represented 83% of gross receivables at quarter-end.
- Costs and operations: Management cited inflation, supply-chain disruption, labor shortages, project delays, and lingering COVID-19 effects as risks to costs, deliveries, demand, and results.
- Medical joint venture: The Clarity Labs joint venture was being wound down in Q4 2022 as COVID-related restrictions and testing activity declined.
- Legal matters: The parties in the HOLA litigation reached a global settlement in principle after mediation on September 23, 2022; written settlement documents were still pending, and no loss or recovery was estimated. The company also disclosed other active litigation, including the Osang dispute, for which outcomes were uncertain.
- Other items: The company recorded $0.49 million of other income for the first nine months, primarily from escrow funds associated with the SG Echo acquisition. Lago Vista property assets of $4.45 million were classified as held for sale. A share repurchase program authorized up to 1 million shares; 23,115 shares had been repurchased for $49,680 through September 30.
Important facts for investors to verify
- Confirm the issuer identity: the supplied filing is SG Blocks, Inc., not Olenox Industries Inc.
- Reconcile reported figures across the filing: the MD&A gives a different nine-month common-stockholder loss than the financial statements, and its equity figure also differs from the balance sheet.
- Assess near-term liquidity, the January 2023 note maturity, and the need and availability of additional financing in light of management’s stated going-concern uncertainty.
- Verify the status, timing, margins, and cancellation exposure of the ATCO contract and other backlog; clarify how the $5.95 million contract relates to the $2.59 million reported ending backlog.
- Monitor customer concentration, receivable collections, medical revenue decline, and the financial effects of winding down the Clarity Labs venture.
- Check execution of the HOLA settlement and developments in other litigation, as the filing did not quantify potential outcomes.